Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Consulting
  • Workshops
  • Books
  • Blog
  • Case Studies
  • Resources
  • Hall of Fame
  • Contact
  • Free E Book
  • Digital Magazine

Quality and Safety updates-

12/23/2009

0 Comments

 
FDA says Vytorin link to cancer risk is unlikely.
According to reports from the US Food and Drug Administration, it is not likely that two cholesterol medications, Vytorin (ezetimibe and simvastatin) and Zetia (ezetimibe), increase an individual's cancer risk. However, the agency said that it cannot completely rule out an association between the drugs and an increased risk of cancer.  

Further it states that it has examined all of the data from the" Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, which "first raised the alarm about a possible risk and showed that significantly more subjects treated with Vytorin developed and died from all types of cancer when compared with those taking placebo."

The FDA report supposedly further states that it is not advising doctors or consumers to stop using any of the...medications, but will continue to evaluate the clinical benefits and potential risks of Vytorin and Zetia compared to other cholesterol-lowering drugs it has approved." 

Chemotherapy drugs may cross blood-brain barrier, disrupt brain cell regeneration.
According to research published in the journal Cancer Investigation, four chemotherapy drugs "caused a significant breakdown in brain cell regeneration" in rodents. In fact, researchers found "a 15.4 percent reduction in new brain cells after use of fluorouracil, a 30.5% reduction following cyclophosphamide, a 22.4% reduction following doxorubicin, and a 36% reduction following paclitaxel." The researchers suggested that "all...chemo drugs cross into the brain after all, or that they act via peripheral mechanisms, such as inflammation, that could open up the blood-brain barrier."  

Some doctors, researchers concerned generics may not work as well as brand-name drugs.
A column in the NewYork Times, Lesley Alderman wrote that "there is a gnawing concern among some doctors and researchers that certain prescription generic drugs may not work as well as their brand-name counterparts." Cardiologists and neurologists in particular are concerned about variations in generic formulations that "could have a serious effect on a patient's health." But, insurers cite research that shows "no difference in hospitalizations or emergency-room visits for people on brand-name epilepsy drugs compared with those taking generics." For its part, the FDA "says it stands behind generic medications and its methods of approving them." Gary J. Buehler, director of the FDA's office of generic drugs, said the agency has "not seen any scientific studies that show generics do not hold up as well as brand name drugs."
 

Cold capsules recalled.
According to a report published in the American Press, consumer-product maker "Procter & Gamble Co. is recalling 700,000 packs of Vicks DayQuil [acetaminophen, dextromethorphan, doxylamine, pseudoephrine] capsules because they are not childproof," in spite of "labeling claims on the box" that they are. Specifically, P&G is recalling DayQuil Cold & Flu 24-Count LiquiCaps Bonus Pack. According to a P&G spokeswoman, "the product was distributed nationally between September 2008 and February 2009, and more recently between September and December this year." 
 

Small infection risk with antibiotic-free intravitreal drug injections.
 According to report published in the Dec. issue of the Archives of Ophthalmology, "intravitreal drug injections led to an infection rate of less than one in 1,000 with a protocol that avoided antibiotics and sterile gloves and drape." After analyzing data on "a total of 3,838 intravitreal injections" of ranibizumab or triamcinolone "administered to 733 eyes by 124 physicians," researchers found that "only three cases of culture-positive endophthalmitis occurred following intravitreal injection." Notably, "in about a third of cases, patients received antibiotics before and after injection, but in the remaining two-thirds, patients received antibiotics before or after the procedure or not at all."  
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    New Book Released!

    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat

    Shruti's books...

    Picture
    Picture
    shruti bhat, business process management, continuous improvement
    Picture
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management

    New Online Course Released!

    ​Kaizen Leader Certification
    ​Masterclass
    kaizen leader masterclass for pharmaceuticals, shruti bhat
    Picture

    Shruti Bhat
    PhD Tech MBA
    Certified Lean Six Sigma Black Belt

    Shruti is a Global Business Excellence and Continuous Improvement Leader.

    Shruti is true Thought Leader with over 10 years of demonstrated accomplishments, industry awards, certifications, books, patents and several publications in peer reviewed journals.

    Shruti is appreciated for her knowledge, integrity, innovation, and collaborative team approach with effective mentoring as her organizational leadership style.
    About Shruti Bhat

    Blog Categories

    All
    3D Printing
    5S
    Artificial Intelligence
    Biotechnology
    Books
    Case Studies
    CMMI
    Continuous Improvement
    Cosmetics & Personal Products
    Design Thinking
    Drug Discovery
    Food Industry
    Hall Of Fame
    Health Care
    Innovation
    ISO
    Just In Time
    Kaizen
    LEAN
    Lean Six Sigma
    Manufacturing
    Medical Apps
    Medical Devices
    Motivational Cards
    Nanotechnology
    Novel Drug Delivery
    Operations
    Orphan Drugs
    Packaging & Logistics
    Patents
    Pharma Research
    Precision Medicine
    Process Improvement
    Product Development
    Productivity Improvement
    QbD
    Quality By Design
    Quality- By-Design
    Quality Management
    Rare Diseases
    Robotics
    Service Industry
    Six Sigma
    Targeted Drug Delivery
    TQM
    Videos
    Voice Of Customer
    Workshops

    Attention Readers!

    The information posted here (not limited to blog, website, podcasts, videos, Inno-ideas slides, slide-shows, whitepapers and other downloadable 'free' resources) is Copyright protected, 'for review and reference' purpose only. Not to be copied, sold, distributed or used without prior authorization by Dr. Shruti U Bhat. Any instance(s) found to the contrary would be construed as copyright violation, illegal, plagiarism and/or could be subject to legal proceedings.

    For additional details, refer our
    Terms & Conditions for site usage.

    More Books...

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Health & Wellness

    Picture


    Kaizen Certification Online Courses

    kaizen leader certification, kaizen champion certification, kaizen orientation training, process efficiency expert certification, kaizen tools, kaizen leader for pharmaceuticals, kaizen certification, kaizen training, shruti bhat
© Copyright 1992- 2019 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media